32978-68-0

Basic information

• Product Name: Carbonic acid, 4-(chlorosulfonyl)phenyl ethyl ester
• Synonyms: 4-Aethoxycarbonyloxy-benzolsulfonylchlorid;4-ethoxycarbonyloxy-benzenesulfonyl chloride
• CAS NO: 32978-68-0
• Molecular Formula: C9H9ClO5S
• Molecular Weight: 264.686
• Mol File: 32978-68-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 71 °C
• Boiling Point: 363.8±34.0 °C(Predicted)
• Density: 1.418±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Carbonic acid, 4-(chlorosulfonyl)phenyl ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbonic acid, 4-(chlorosulfonyl)phenyl ethyl ester(32978-68-0)
• EPA Substance Registry System: Carbonic acid, 4-(chlorosulfonyl)phenyl ethyl ester(32978-68-0)

Safety Data

• Hazardous Substances Data: 32978-68-0(Hazardous Substances Data)

Upstream product

• 14180-05-3 4-ethoxycarbonyloxy-benzenesulfonic acid ; sodium salt 
• 541-41-3 chloroformic acid ethyl ester 
• 825-90-1 sodium p-hydroxybenzenesulfonate 
• 30145-40-5 potassium phenol-4-sulfonate 

Downstream Products

• 872825-57-5 4-hydroxy-benzenesulfonic acid pyrazin-2-ylamide 
• 100128-21-0 4-hydroxy-benzenesulfonic acid-(5-isopropyl-[1,3,4]thiadiazol-2-ylamide) 
• 62287-53-0 phenyl 4-hydroxybenzenesulfonate 
• 705556-59-8 ethyl 4-[(8-fluoro-6-methylphenanthridin-5(6H)-yl)sulfonyl]phenyl carbonate 
• 877814-66-9 N-butyl-4-hydroxy-N-phenylbenzenesulfonamide 
• 874216-84-9 ethyl 4-{[(2S)-2-ethyl-7-fluoro-3-oxo-3,4-dihydroquinoxalin-1(2H)-yl]sulfonyl}phenyl carbonate 
• 888203-33-6 ethyl 4-{[(2R)-2-ethyl-6-fluoro-3-oxo-3,4-dihydroquinoxalin-1(2H)-yl]sulfonyl}phenyl carbonate 

Relevant articles and documents

Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors

The present invention concerns a method of treatment or prevention of myocardial ischemia-reperfusion injury by diagnosing that a person is in need of treatment or prevention of myocardial ischemia-reperfusion injury and administering a therapeutically ef

Methods of treating atherosclerosis using NF-kB inhibitors

The present invention concerns a method of treating atherosclerosis by diagnosing that a person is in need of treatment for atherosclerosis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by inte

METHODS OF TREATING ATHEROSCLEROSIS USING NF-kB INHIBITORS

The present invention concerns a method of treating atherosclerosis by diagnosing that a person is in need of treatment for atherosclerosis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by inte